La vendita allo scoperto per Medtronic dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Medtronic. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Medtronic (NYSE:MDT) Azioni, Report sulle vendite allo scoperto

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

BIDU

SOHU

Analisi pre-market delle performance attese, utili trimestrali e potenziali movimenti capaci di influenzare i mercati globali.

Medtronic, Fluor e altre 3 azioni da tenere d&#39;occhio nella giornata di martedì

Long Ideas

Media

$BTC

ABBV

COIN

CRNC

Durante il programma &#34;Mad Money Lightning Round&#34; della CNBC, Jim Cramer ha consigliato l’acquisto di AbbVie Inc. (NYSE:ABBV) affermando che si tratta di un &#34;gioiello&#34; e di un &#34;vincitore&#34;. Ha aggiunto: &#34;Non posso credere che il titolo sia sceso così tanto&#34;.

Jim Cramer: è tempo di fare cassa? Ecco la sua strategia

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MediaTek Inc

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

Reported Sunday, Medtronic Evolut TAVR Demonstrates Sustained Valve Performance And Lower Cardiovascular Mortality Trend At 5 Years

On Sunday, Chinese Vice Premier He Lifeng met with top executives from Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Cargill, and other major firms.
What Happened: "China will continue to improve the business environment and welcome more investment by multinational companies in China, sharing opportunities for development," he told the leaders, describing the country's economy as "highly resilient" and "full of vitality."
Executives from medical device maker Medtronic PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and investment management firm Conning were also in attendance, reported Reuters, citing a statement from China's Ministry of Commerce.
However, the statement did not specify where the meeting took place.
Many of the executives are in Beijing to attend the China Development Forum, where further high-level meetings, including a possible session with President Xi Jinping, are expected later this week, the report noted, citing unnamed sources.
See Also:&nbsp;<a href="https://www.benzinga.com/25/03/44272657/alibaba-chairperson-says-everyone-is-concerned-about-tariffs-as-he-expects-levies-on-chinese-evs" target="_blank" rel="noreferrer noopener">Alibaba's Joseph Tsai Says ‘Everyone Is Concerned About Tariffs,' As He Expects Levies On Chinese EVs</a>
Why It's Important: Beijing has ramped up efforts to attract foreign capital amid a slowing economy and fresh <a href="https://in.benzinga.com/news/global/25/03/44448798/china-ponders-export-limitations-to-quell-trumps-trade-onslaught">U.S. tariff headwinds</a> under President Donald Trump.
While American companies made up the largest group at this year's forum, sources say fewer U.S. CEOs attended compared to last year—signaling ongoing caution in cross-border corporate relations, the report noted.
Previously, the Chinese President expressed concerns about the possibility of China facing isolation similar to the Soviet Union during the Cold War. The ongoing trade war has heightened <a href="https://in.benzinga.com/25/03/44161587/is-china-apprehensive-of-losing-the-trade-war-to-the-us-china-could-get-isolated-like-moscow-fears-xi-jinping">fears of economic isolation</a>.
 Despite these challenges, <a href="https://in.benzinga.com/general/market-summary/25/03/44273552/ray-dalio-says-china-is-way-ahead-in-ai-and-robotics-us-lags-in-mass-production">China remains a leader</a> in technological advancements, particularly in artificial intelligence and robotics, according to investor Ray Dalio.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/44055314/mrbeast-lost-millions-on-amazons-beast-games-now-hes-looking-to-raise-hundreds-of-millions-to-take-h" target="_blank" rel="noreferrer noopener">MrBeast Lost Millions On Amazon's ‘Beast Games'—Now He's Looking To Raise Hundreds Of Millions To Take His Brand To The Next Level</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Economics

Tech

AAPL

China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment'

High-rolling investors have positioned themselves bullish on Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in MDT often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for Medtronic. This is not a typical pattern.
The sentiment among these major traders is split, with 62% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $38,125, and 7 calls, totaling $895,860.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $82.5 to $92.5 for Medtronic over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Medtronic's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Medtronic's whale activity within a strike price range from $82.5 to $92.5 in the last 30 days. 
<h3>Medtronic 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742576490_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.35</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$85.00</td>
<td>$287.2K</td>
<td>4.0K</td>
<td>1.9K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.0</td>
<td>$3.85</td>
<td>$3.85</td>
<td>$90.00</td>
<td>$220.6K</td>
<td>1.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.4</td>
<td>$5.3</td>
<td>$5.4</td>
<td>$87.50</td>
<td>$205.2K</td>
<td>419</td>
<td>390</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.45</td>
<td>$4.35</td>
<td>$4.35</td>
<td>$87.50</td>
<td>$54.8K</td>
<td>588</td>
<td>126</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.94</td>
<td>$1.8</td>
<td>$1.84</td>
<td>$90.00</td>
<td>$48.1K</td>
<td>916</td>
<td>409</td>
</tr>
</tbody>
</table>

<h3>About Medtronic</h3>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Following our analysis of the options activities associated with Medtronic, we pivot to a closer look at the company's own performance.
<h3>Current Position of Medtronic</h3>
<ul>
<li>With a trading volume of 3,457,096, the price of MDT is down by -0.69%, reaching $90.59.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 62 days from now.</li>
</ul>
<h3>Expert Opinions on Medtronic</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $107.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Citigroup upgrades its rating to Buy with a revised price target of $107. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Medtronic, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Looking At Medtronic's Recent Unusual Options Activity

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/embolization-device-recall-and-correction-medtronic-removes-unused-027-compatible-pipeline-vantage#:~:text=Medical%20Device%20Recalls-,Embolization%20Device%20Recall%20and%20Correction%3A%20Medtronic%20Removes%20Unused%20027%20Compatible,Wall%20Apposition%20and%20Braid%20Deformation" title="https://www.fda.gov/medical-devices/medical-device-recalls/embolization-device-recall-and-correction-medtronic-removes-unused-027-compatible-pipeline-vantage#:~:text=Medical%20Device%20Recalls-,Embolization%20Device%20Recall%20and%20Correction%3A%20Medtronic%20Removes%20Unused%20027%20Compatible,Wall%20Apposition%20and%20Braid%20Deformation">https://www.fda.gov/medical-devices/medical-device-recalls/embolization-device-recall-and-correction-medtronic-removes-unused-027-compatible-pipeline-vantage#:~:text=Medical%20Device%20Recalls-,Embolization%20Device%20Recall%20and%20Correction%3A%20Medtronic%20Removes%20Unused%20027%20Compatible,Wall%20Apposition%20and%20Braid%20Deformation</a>

Biotech

General

FDA Says Medtronic Removes Unused 027 Compatible Pipeline Vantage Embolization Device With Shield Technology; Medtronic Updates Use Instructions For 021 Compatible Pipeline Vantage Embolization Devices; Medtronic Updates Instructions For Using Pipeline Vantage 021 Device Models Due To Risk Of Incomplete Wall Apposition & Braid Deformation

CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trial&nbsp;to primarily enroll women using the two most widely used global TAVR devices

Reported Sunday, Medtronic Evolut TAVR Demonstrates Superior Durability And Valve Function In Small Annulus Patients, SMART Trial Shows

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>DA Davidson analyst Rudy Kessinger upgraded the rating for Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) from Neutral to Buy and raised the price target from $90 to $125. Okta shares closed at $87.16 on Monday. <a href="https://www.benzinga.com/quote/okta/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Aman Rakkar upgraded the rating for HSBC Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSBC#NYSE">HSBC</a>) from Equal-Weight to Overweight. HSBC shares closed at $60.33 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Joanne Wuensch upgraded Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Neutral to Buy and raised the price target from $92 to $107. Medtronic shares closed at $94.30 on Monday. <a href="https://www.benzinga.com/quote/mdt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Julien Dumoulin-Smith upgraded The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) from Underperform to Neutral and raised the price target from $11 to $13. AES shares closed at $11.19 on Monday. <a href="https://www.benzinga.com/quote/aes/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Jeffrey Hammond upgraded the rating for Nordson Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) from Sector Weight to Overweight and maintained the price target of $260. Nordson shares closed at $207.10 on Monday. <a href="https://www.benzinga.com/quote/ndsn/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3"> Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Upgrades

Price Target

Analyst Ratings

HSBC

NDSN

OKTA

This Medtronic Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Throughout the last three months, 5 analysts have evaluated Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Medtronic and provided 12-month price targets. The average target is $97.4, accompanied by a high estimate of $107.00 and a low estimate of $89.00. Witnessing a positive shift, the current average has risen by 4.73% from the previous average price target of $93.00.
<img src="https://www.benzinga.com/files/images/story/2025/1741093276_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Medtronic among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$91.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$89.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Medtronic. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Medtronic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Medtronic's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Medtronic analyst ratings.</a>
<h2>Delving into Medtronic's Background</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>Unraveling the Financial Story of Medtronic</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Medtronic's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.51% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 15.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Medtronic's ROE stands out, surpassing industry averages. With an impressive ROE of 2.64%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Medtronic's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.44% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average at 0.54, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Medtronic's Future

Citigroup analyst Joanne Wuensch upgrades Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Neutral to Buy and raises the price target from $92 to $107.

Citigroup Upgrades Medtronic to Buy, Raises Price Target to $107

On Monday, the FDA approved Medtronic plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43911731/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-p" rel="noreferrer noopener">with Parkinson&#8217;s disease</a>.
Deep brain stimulation uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders.
Medtronic has enhanced its Percept DBS neurostimulators with exclusive BrainSense Adaptive technology for Parkinson&#8217;s.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43782957/medtronic-q3-earnings-cardiovascular-and-neuroscience-drive-growth-surgical-revenue-dips-reaffirms-annual-forecast" rel="noreferrer noopener">Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast</a>
This feature personalizes therapy based on a patient&#8217;s brain activity in real-time – both in clinical settings and daily life.
It provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation.
BrainSense Adaptive DBS is available to Medtronic DBS patients with Parkinson&#8217;s who have been implanted with a Percept neurostimulator and future Medtronic DBS patients.
The Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson&#8217;s Disease (ADAPT-PD) trial highlights the potential of aDBS in clinical practice.
The FDA approval also includes the Medtronic BrainSense Electrode Identifier (EI), which helps reduce patient time spent in clinic to program their DBS settings. Using EI, clinicians can conduct an accurate and precise initial programming, 85% faster than traditional electrode selection.
BrainSense aDBS and EI are also&nbsp;available&nbsp;in&nbsp;Europe. Patient programs in&nbsp;the United States&nbsp;will begin at select healthcare systems over the coming weeks, with availability nationwide in the coming months.
Price Action: MDT stock is up 0.85% at $90.70 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43910982/apple-commits-500-billion-in-us-investment-for-ai-push-boost-us-manufacturing-tech" target="_blank" rel="noreferrer noopener">Apple Commits $500 Billion In US Investment For AI Push, Boost US Manufacturing Tech</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

FDA Approves Medtronic's Adaptive Deep Brain Stimulation System For Parkinson's Patients

New closed-loop system self-adjusts DBS therapy to individual brain activity&nbsp;in real time; the largest commercial launch of brain-computer interface technology ever&nbsp;
GALWAY, Ireland, Feb. 24, 2025 /PRNewswire/ --&nbsp;For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense&#x2122; Adaptive deep brain stimulation (aDBS) and BrainSense&#x2122; Electrode Identifier (EI).
There is no cure for debilitating neurological conditions like Parkinson's, however, deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. DBS is similar to a cardiac pacemaker, but for the brain. It uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders.
Now Medtronic has enhanced its Percept&#x2122; DBS neurostimulators with exclusive BrainSense&#x2122; Adaptive technology†, introducing aDBS for people living with Parkinson's. This feature personalizes therapy based on a patient's brain activity in real time – both in clinical settings and in daily life2. It provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation.

Medtronic Earns U.S. FDA Approval For The World's First Adaptive Deep Brain Stimulation System For People With Parkinson's

RBC Capital analyst Shagun Singh reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and maintains $105 price target.

Reiteration

RBC Capital Reiterates Outperform on Medtronic, Maintains $105 Price Target

UBS analyst Danielle Antalffy maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and raises the price target from $85 to $95.

UBS Maintains Neutral on Medtronic, Raises Price Target to $95

Baird analyst David Rescott maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and raises the price target from $90 to $91.

Baird Maintains Neutral on Medtronic, Raises Price Target to $91

Needham analyst Mike Matson reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Hold to Hold.

Needham Reiterates Hold on Medtronicto Hold

Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC<a href="https://www.benzinga.com/25/02/43784079/us-stocks-mixed-ny-state-business-activity-rises-in-february"> minutes on Wednesday.</a>
U.S. and Russian officials met in Saudi Arabia Tuesday <a href="https://www.benzinga.com/news/global/25/02/43787369/us-russian-officials-begin-ukraine-peace-talks-defense-sector-stocks-rise">to begin</a> peace negotiations, marking their first high-level talks on the war in Ukraine since Russia&#8217;s invasion in 2022. The initial talks were intended as "trust-building" and could lay the groundwork for a future meeting between President Donald Trump and Russian President Vladimir Putin. Ukrainian and other European officials were notably absent from Tuesday's discussions. 
WTI crude oil futures held steady as diplomatic talks between the U.S. and Russia raised hopes for reduced geopolitical risks. 
Read Next: <a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a>
The yield on the 10-year US Treasury note rose 0.04%, back above the 4.5% threshold as investors digested recent comments from Fed officials, including Christopher Waller, Michelle Bowman and Patrick Harker, which reinforced expectations that interest rates will remain on hold in the near term.  
All eyes will be on Wednesday's release of the latest FOMC's minutes set for 2 p.m. ET. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 0.57% to $88.64.&nbsp;
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was down 1.16% to $94,672 as crypto markets fell broadly Tuesday.&nbsp;&nbsp;
<h2 class="wp-block-heading">Tuesday's Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,000.73</td>
<td>-0.12%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,115.46</td>
<td>0.01%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,454.56</td>
<td>-0.19%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,288.09</td>
<td>0.36%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched up 0.1% to $610.31.&nbsp;</li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 0.17% at $445.03.&nbsp;</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.04% to $538.36.&nbsp;</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.44% to $226.97.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) dipped 0.53% to $225.81.&nbsp;</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) rose 0.95% to $90.93.&nbsp;</li>
</ul>
<h2 class="wp-block-heading">Tuesday's Stock Movers:&nbsp;</h2>
Shares of Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) surged following reports suggesting Broadcom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Taiwan Semiconductor Manufacturing Co. Ltd.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) are <a href="https://www.benzinga.com/markets/equities/25/02/43775200/intel-jumps-over-5-in-tuesday-pre-market-as-deal-talks-with-broadcom-and-tsmc-surface">considering bids</a> for portions of the company.
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Baidu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)&nbsp;</li>
<li>Constellation Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)&nbsp;</li>
<li>Franklin Electric Co., Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FELE#NASDAQ">FELE</a>)&nbsp;</li>
<li>Watsco, Inc.&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>)&nbsp;</li>
<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>)&nbsp;</li>
<li>Donnelley Financial Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFIN#NYSE">DFIN</a>)&nbsp;</li>
<li>Fluor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>)&nbsp;</li>
<li>Medtronic Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)&nbsp;</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)&nbsp;</li>
<li>Entergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>)&nbsp;</li>
<li>iQIYI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>)&nbsp;</li>
</ul>
Companies reporting after Tuesday's closing bell include:&nbsp;
<ul>
<li>Occidental Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>)&nbsp;</li>
<li>Matador Resources Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>)&nbsp;</li>
<li>Devon Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)&nbsp;</li>
<li>Bumble, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>)&nbsp;</li>
<li>Sonoco Products Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>)&nbsp;</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>)&nbsp;</li>
<li>Star Bulk Carriers Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBLK#NASDAQ">SBLK</a>)&nbsp;</li>
<li>Shift4 Payments, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>)&nbsp;</li>
<li>Matador Resources Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>)</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/02/43732115/explosion-rocks-chernobyl-nuclear-site-as-zelenskyy-signals-readiness-for-peace-talks">Explosion Rocks Chernobyl Nuclear Site As Zelenskyy Signals Readiness For Peace Talks</a>&nbsp;</li>
</ul>
Image: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Market Summary

Broad U.S. Equity ETFs

Commodities

Global

Federal Reserve

Movers

ETFs

AVGO

AXSM

BMBL

DFIN

SPDR Dow Jones Industrial Average ETF Trust

FELE

FOUR

INTC

MTDR

SBLK

iShares Trust Barclays 20+ Year Treasury Bond Fund

Select Sector SPDR-Consumer Discretionary

US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday?

Tuesday,&nbsp;Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported third-quarter 2025 sales of $8.29 billion, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $8.32 billion</a>.
The medical device maker reported adjusted EPS of $1.39, beating the consensus of $1.36. Revenue increased 2.5% year over year, as reported,&nbsp;and 4.1% organically.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/42859544/anteris-technologies-positioned-to-capture-4-5-of-us-transcatheter-valve-replacement-market-by-2030-analyst" rel="noreferrer noopener">Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst</a>
&#8220;We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth,&#8221; said&nbsp;Geoff Martha, Medtronic chairman and chief executive officer.
&#8220;We are starting to see the results from our long-term investments in groundbreaking innovation, such as pulsed-field ablation, to drive growth in some of the most attractive markets in MedTech.&#8221;
Cardiovascular segment revenue reached&nbsp;$3.04 billion, up 3.7% year over year as reported, and&nbsp;increased 5% organically, with mid-single digit increases in Cardiac Rhythm &amp; Heart Failure and Structural Heart &amp; Aortic and a low-single-digit increase in Coronary &amp; Peripheral Vascular, all on <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43776497/medtronic-reports-third-quarter-fiscal-2025-financial-results" rel="noreferrer noopener">an organic basis</a>.
Neuroscience revenues of&nbsp;$2.46 billion&nbsp;increased 4.4% as reported and 5.2% organically, with a low-double-digit increase in Neuromodulation, mid-single-digit increase in Cranial &amp; Spinal Technologies, and low-single-digit increase in Specialty Therapies, all on an organic basis.
Medical Surgical revenue of $2.07 billion decreased by 1.9% as reported and by 0.4% organically, with flat organic results in Surgical &amp; Endoscopy and a low-single-digit organic decline in Acute Care &amp; Monitoring.
Diabetes revenue of&nbsp;$694 million&nbsp;increased by 8.4%, as reported, and by 10.4% organic.
Guidance:&nbsp;Medtronic reaffirms its fiscal year 2025 organic revenue <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/42069216/medtronic-q2-earnings-diabetes-and-neuroscience-revenue-boost-growth-raises-annual-outlook" rel="noreferrer noopener">growth guidance of 4.75%-5%</a>.
If recent foreign currency exchange rates hold, FY25 revenue growth would be around 3.4%-3.8%. If recent foreign currency exchange rates hold, 2025 revenue growth on an adjusted basis would be 3.4%-3.9%.
Medtronic expects 2025 adjusted EPS of $5.44-$5.50 versus consensus of $5.45.
Price Action: MDT stock is down 5.94% at $87.30 during the premarket session at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43778628/fda-approves-gsks-5-in-1-meningococcal-vaccine-for-adolescents-ahead-of-cdc-advisory-committee-vote-meeting-next-week" target="_blank" rel="noreferrer noopener">FDA Approves GSK&#8217;s 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week</a></li>
</ul>
Photo via Shutterstock

Guidance

Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast

CORRECTION: Medtronic Affirms FY25 Adj EPS Outlook of $5.44-$5.50 vs $5.45 Estimate; Narrows FY25 Sales Guidance from $33.46B-$33.63B To $33.46B-$33.59B vs $33.54B Estimate

WIIM

Medtronic shares are trading lower after the company reported mixed Q3 financial results and issued FY25 adjusted EPS guidance below estimates.

Medtronic Reaffirms Its FY25 Organic Revenue Growth Guidance Of 4.75%-5%

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported quarterly earnings of $1.39 per share which beat the analyst consensus estimate of $1.36 by 2.21 percent. This is a 6.92 percent increase over earnings of $1.30 per share from the same period last year. The company reported quarterly sales of $8.29 billion which missed the analyst consensus estimate of $8.32 billion by 0.39 percent. This is a 2.51 percent increase over sales of $8.09 billion the same period last year.

Medtronic Q3 2025 Adj EPS $1.39 Beats $1.36 Estimate, Sales $8.29B Miss $8.32B Estimate

Management

Press Releases

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Medtronic to announce financial results for its third quarter of fiscal year 2025

Medtronic reports third quarter fiscal 2025 financial results

Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's

Dividends

Medtronic announces cash dividend for fourth quarter of fiscal year 2025

SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients

CGS Transforms Workplace Training with Cicero,  a New AI-Driven, Customizable Roleplay Platform

Artificial Intelligence Influence on Healthcare Industry Reaching All Time Highs for Diagnostics and Treatments

Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

ACON

AVAI

OBIO

TDOC

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Citigroup

RBC Capital

Baird

Truist Securities

Screenshot 2024-10-03 at 5.30.47 PM

DXCM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit